Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency

NCT04899310 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT04899310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04899310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
August 6, 2021
Completion date
April 1, 2026
Enrollment
18 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

methylmalonic acidemia